Cargando…

帕博利珠单抗联合安罗替尼四线治疗EGFR基因敏感突变阳性肺腺癌1例

45.7% of Chinese patients with advanced lung adenocarcinoma were reported to harbour sensitizing epidermal growth factor receptor (EGFR) mutations. Limited therapeutic options are left for non-small cell lung cancer (NSCLC) harbouring sensitizing EGFR mutations after failure of EGFR-tyrosine kinase...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 中国肺癌杂志编辑部 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8560986/
https://www.ncbi.nlm.nih.gov/pubmed/34628779
http://dx.doi.org/10.3779/j.issn.1009-3419.2021.102.25
_version_ 1784593038770700288
collection PubMed
description 45.7% of Chinese patients with advanced lung adenocarcinoma were reported to harbour sensitizing epidermal growth factor receptor (EGFR) mutations. Limited therapeutic options are left for non-small cell lung cancer (NSCLC) harbouring sensitizing EGFR mutations after failure of EGFR-tyrosine kinase inhibitor (TKI) therapy and chemotherapy, finding effective options for them is an unmet clinic need. Herein we reported a case that till January 12, 2021, an 82-year-old female with sensitizing EGFR-mutant advanced lung adenocarcinoma received a surprising progression-free survival (PFS) benefit of over 21 months from the combination therapy of pembrolizumab and anlotinib after her failure of treatments of osimertinib, chemotherapy and anlotinib-monotherapy.
format Online
Article
Text
id pubmed-8560986
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher 中国肺癌杂志编辑部
record_format MEDLINE/PubMed
spelling pubmed-85609862021-11-10 帕博利珠单抗联合安罗替尼四线治疗EGFR基因敏感突变阳性肺腺癌1例 Zhongguo Fei Ai Za Zhi 病例报道 45.7% of Chinese patients with advanced lung adenocarcinoma were reported to harbour sensitizing epidermal growth factor receptor (EGFR) mutations. Limited therapeutic options are left for non-small cell lung cancer (NSCLC) harbouring sensitizing EGFR mutations after failure of EGFR-tyrosine kinase inhibitor (TKI) therapy and chemotherapy, finding effective options for them is an unmet clinic need. Herein we reported a case that till January 12, 2021, an 82-year-old female with sensitizing EGFR-mutant advanced lung adenocarcinoma received a surprising progression-free survival (PFS) benefit of over 21 months from the combination therapy of pembrolizumab and anlotinib after her failure of treatments of osimertinib, chemotherapy and anlotinib-monotherapy. 中国肺癌杂志编辑部 2021-10-20 /pmc/articles/PMC8560986/ /pubmed/34628779 http://dx.doi.org/10.3779/j.issn.1009-3419.2021.102.25 Text en 版权所有©《中国肺癌杂志》编辑部2021 https://creativecommons.org/licenses/by/3.0/This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 3.0) License. See: https://creativecommons.org/licenses/by/3.0/.
spellingShingle 病例报道
帕博利珠单抗联合安罗替尼四线治疗EGFR基因敏感突变阳性肺腺癌1例
title 帕博利珠单抗联合安罗替尼四线治疗EGFR基因敏感突变阳性肺腺癌1例
title_full 帕博利珠单抗联合安罗替尼四线治疗EGFR基因敏感突变阳性肺腺癌1例
title_fullStr 帕博利珠单抗联合安罗替尼四线治疗EGFR基因敏感突变阳性肺腺癌1例
title_full_unstemmed 帕博利珠单抗联合安罗替尼四线治疗EGFR基因敏感突变阳性肺腺癌1例
title_short 帕博利珠单抗联合安罗替尼四线治疗EGFR基因敏感突变阳性肺腺癌1例
title_sort 帕博利珠单抗联合安罗替尼四线治疗egfr基因敏感突变阳性肺腺癌1例
topic 病例报道
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8560986/
https://www.ncbi.nlm.nih.gov/pubmed/34628779
http://dx.doi.org/10.3779/j.issn.1009-3419.2021.102.25
work_keys_str_mv AT pàbólìzhūdānkàngliánhéānluōtìnísìxiànzhìliáoegfrjīyīnmǐngǎntūbiànyángxìngfèixiànái1lì
AT pàbólìzhūdānkàngliánhéānluōtìnísìxiànzhìliáoegfrjīyīnmǐngǎntūbiànyángxìngfèixiànái1lì
AT pàbólìzhūdānkàngliánhéānluōtìnísìxiànzhìliáoegfrjīyīnmǐngǎntūbiànyángxìngfèixiànái1lì
AT pàbólìzhūdānkàngliánhéānluōtìnísìxiànzhìliáoegfrjīyīnmǐngǎntūbiànyángxìngfèixiànái1lì
AT pàbólìzhūdānkàngliánhéānluōtìnísìxiànzhìliáoegfrjīyīnmǐngǎntūbiànyángxìngfèixiànái1lì